Amplify Weight Loss Drug & Treatment ETF (THNR)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreTop 10 Holdings (59.75% of Total Assets)
Sector Weightings
Overall Portfolio Composition (%)
| Stocks | 96.05% |
| Bonds | 0.00% |
|---|
Equity Holdings
| Price/Earnings | 0.05 |
| Price/Book | 0.24 |
|---|---|
| Price/Sales | 0.2 |
| Price/Cashflow | 0.07 |
| Median Market Cap | -- |
| 3 Year Earnings Growth | -- |
Bond Ratings
| US Government | 0.00% |
| AAA | -- |
|---|---|
| AA | -- |
| A | -- |
| BBB | -- |
| BB | -- |
| B | -- |
| Below B | -- |
| Other | -- |
ETF Summary
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
ETF Overview
| Category | Health |
|---|---|
| Fund Family | Amplify ETFs |
| Net Assets | 5.78M |
| YTD Daily Total Return | 0.54% |
| Yield | 1.64% |
| Legal Type | Exchange Traded Fund |
